+1-510-404-8135
The Latin America liquid biopsy market is anticipated to reach $70.9 million by 2025, witnessing a CAGR of 10.29% in the forecast period 2019-2025.
Liquid biopsy is a minimal invasive medical procedure with the ability to detect the presence of molecular cancer biomarkers in the biological fluids. The test principally involves the usage of samples of biological fluids, such as blood, urine, serum, and saliva, and then the analysis of the samples using different techniques, such as next-generation sequencing (NGS) and polymerase chain reaction (PCR) to detect the mutations known to cause cancer. The liquid biopsy tests provide a platform to an oncologist for a non-invasive and highly-sensitive tumor profiling of patients. The test provides actionable information about the patients at every critical stage of the treatment cycle. Liquid biopsy tests help in the early detection of tumor-associated mutations in the blood with the help of ctDNA, thus further helping in the betterment of cancer treatment procedure. Growing geriatric population has significantly necessitated the requirement for novel diagnostic procedures based on minimal invasive procedures. Significant degree of research on molecular technologies, cancer biomarkers, and biomarkers presence in body fluids has opened various pathways for the development of a vital non-invasive diagnostic procedure as liquid biopsy.
The purpose of this study is to gain a holistic view of the Latin America liquid biopsy market in terms of various influencing factors, such as recent trends, regulatory frameworks, and technological advancements in the market. The scope of this report constitutes a detailed study of the different kinds of products associated with the Latin America liquid biopsy market. The market has been segmented into “Product Type”, “Circulating Biomarkers”, “Clinical Application”, “Therapeutic Application”, and “Country”. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market.
This research report aims at answering various aspects of the Latin America liquid biopsy market, with the help of the key factors driving the market, restraints and challenges that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The report includes an in-depth examination of the key players and recent developments taking place in this market. Moreover, the report also includes chapters on market dynamics (market drivers, opportunities, and challenges), and industry analysis as well.
The research study highlights the factors governing the industry attractiveness with Porter’s Five Forces for a comprehensive understanding of the Latin America liquid biopsy market. Moreover, the study includes detailed product mapping, market estimation, and analysis of key trends in multiple regions, growth of liquid biopsy market in each region for different cancer types, and the key strategies and developments by the prominent liquid biopsy market stake holders.
The answers to the following key questions can be derived from this report:
• What are the key features of the liquid biopsy technology promoting its incorporation in different clinical applications?
• What are key advantages of the liquid biopsy technology over tissue biopsy?
• How did the liquid biopsy market evolve and what is its scope in the future?
• What are the major market drivers, challenges, and opportunities in the Latin America liquid biopsy market?
• Which are the leading companies dominating the Latin America liquid biopsy market?
• Which therapeutic application market would witness massive incorporation of the liquid biopsy technology in the forecast period?
• Products based on which circulating biomarker are anticipated to witness massive rise in the demand in the forecast period?
• How would the scope of clinical application of the liquid biopsy technology evolve in the forecast period?
• What are investors’ perceptions about the Latin America liquid biopsy market? Also, who are leading stakeholders of the market holding a significant share in the market’s intellectual property?
• What is the market value of the leading segments and sub-segments of the Latin America liquid biopsy market?
• How will each segment of the Latin America liquid biopsy market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2025?
• How will the industry evolve during the forecast period 2019-2025?
• Which region will contribute to the highest rate of sales of the Latin America liquid biopsy market during the forecast period?
The key players who have been contributing significantly to the Latin America liquid biopsy market are Biocept, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche AG, Illumina, Inc., MDxHealth Inc., Myriad Genetics Inc., NeoGenomics Laboratories, Inc., Qiagen N.V., Thermo Fisher Scientific Inc., Guardant Health, Inc., Menarini Silicon Biosystems, Sysmex Inostics GmbH, MetaCell s.r.o, Contextual Genomics Inc., and Epic Sciences, Inc.
List of Tables
Table: 1.1 Tissue Biopsy vs. Liquid Biopsy
Table: 2.1 Impact Analysis
Table: 2.2 Governmental Initiatives for the Market Growth of Precision Medicine
Table: 2.3 Incidence of Leading Cancer Types (by Country), 2018 and 2040
Table: 7.1 Breast Cancer Incidence in Latin American Countries, 2018, 2020, 2025, and 2030
Table: 7.2 Lung Cancer Incidence in Latin American Countries, 2018, 2020, 2025, and 2030
Table: 7.3 Prostate Cancer Incidence in Latin American Countries, 2018, 2020, 2025, and 2030
Table: 7.4 Colorectal Cancer Incidence in Latin American Countries, 2018, 2020, 2025, and 2030
Table: 7.5 Melanoma Cancer Incidence in Latin American Countries, 2018, 2020, 2025, and 2030
Table: 7.6 Ovarian Cancer Incidence in Latin American Countries, 2018, 2020, 2025, and 2030
Table: 7.7 Stomach Cancer Incidence in Latin American Countries, 2018, 2020, 2025, and 2030
Table: 8.1 Healthcare Expenditure (US$ per head) in Latin American Countries, 2015-2017
Table: 8.2 Brazil: Prevalence of Different Types of Cancer, 2018-2030
Table: 8.3 Mexico: Prevalence of Different Types of Cancer, 2018-2030
Table: 8.4 Argentina: Prevalence of Different Types of Cancer, 2018-2030
Table: 8.5 Chile: Prevalence of Different Types of Cancer, 2018-2030
Table: 8.6 Colombia: Prevalence of Different Types of Cancer, 2018-2030
List of Figures
Figure: 1 Few Citations of Liquid Biopsy
Figure: 2 Latin America Market Drivers and Restraints
Figure: 3 Latin America Liquid Biopsy Market, 2017-2025
Figure: 4 Latin America Liquid Biopsy Market (by Product Type), 2017 and 2025
Figure: 5 Latin America Liquid Biopsy Market (by Circulating Biomarkers), 2017 and 2025
Figure: 6 Latin America Liquid Biopsy Market (by Clinical Application), 2017-2025
Figure: 7 Latin America Liquid Biopsy Market (by Therapeutic Application), 2017-2025
Figure: 8 Latin America Liquid Biopsy Market (by Country), 2017-2025
Figure: 9 Adoption Rate: Tissue Biopsy vs. Liquid biopsy
Figure: 1.1 Different Types of Biomarkers in Liquid Biopsy
Figure: 1.2 Evolution of Liquid Biopsy with Progress in Molecular Technologies and Biomarker Discovery
Figure: 1.3 Workflow Model of Tissue and Liquid Biopsy
Figure: 1.4 Clinical Applications of Liquid Biopsy
Figure: 1.5 Latin America Liquid Biopsy Market, 2017-2025
Figure: 2.1 Market Dynamics of LATAM Liquid Biopsy Market
Figure: 3.1 Market Share Analysis: Latin America Liquid Biopsy Market, 2016 and 2017
Figure: 3.2 Porter’s Five Forces Analysis
Figure: 3.3 Bargaining Power of Suppliers: Overall Impact, 2014-2025
Figure: 3.4 Bargaining Power of Buyers: Overall Impact, 2014-2025
Figure: 3.5 Threat of New Entrant: Overall Impact, 2014-2025
Figure: 3.6 Threat of Substitute Products: Overall Impact, 2014-2025
Figure: 3.7 Intensity of Competitive Rivalry: Overall Impact, 2014-2025
Figure: 4.1 Latin America Liquid Biopsy Market (by Circulating Biomarkers)
Figure: 4.2 Liquid Biopsy Market (by Product Type), 2017-2025
Figure: 4.3 Latin America Liquid Biopsy Market (by Tests/Services), 2017-2025
Figure: 4.4 Latin America Liquid Biopsy Market (by Kits and Consumables), 2017-2025
Figure: 4.5 Latin America Liquid Biopsy Market (by Instruments), 2017-2025
Figure: 5.1 Different Circulating Biomarkers
Figure: 5.2 Latin America Liquid Biopsy Market (by Circulating Biomarkers)
Figure: 5.3 Latin America Liquid Biopsy Market (by Circulating Biomarker), 2017 and 2025
Figure: 5.4 Latin America Liquid Biopsy Market (by ctDNA), 2017-2025
Figure: 5.5 CTCs vs. ctDNA Analysis
Figure: 5.6 Latin America Liquid Biopsy Market (by CTCs), 2017-2025
Figure: 5.7 Latin America Liquid Biopsy Market (by cfDNA), 2017-2025
Figure: 5.8 Latin America Liquid Biopsy Market (by Extracellular Vesicles and Others), 2017-2025
Figure: 6.1 Latin America Liquid Biopsy Market (by Clinical Applications)
Figure: 6.2 Liquid Biopsy Market (by Clinical Application), 2017-2025
Figure: 6.3 Latin America Liquid Biopsy Market (by Treatment Monitoring), 2017-2025
Figure: 6.4 Latin America Liquid Biopsy Market (by Prognosis and Recurrence Monitoring), 2017-2025
Figure: 6.5 Latin America Liquid Biopsy Market (by Treatment Selection), 2017-2025
Figure: 6.6 Latin America Liquid Biopsy Market (by Diagnosis and Screening), 2017-2025
Figure: 7.1 Latin America Liquid Biopsy Market (by Therapeutic Applications)
Figure: 7.2 Latin America Liquid Biopsy Market (by Therapeutic Applications), 2017-2025
Figure: 7.3 Types of Breast Cancer
Figure: 7.4 Latin America Liquid Biopsy Market (by Breast Cancer), 2017-2025
Figure: 7.5 Types of Lung Cancer
Figure: 7.6 Latin America Liquid Biopsy Market (by Lung Cancer), 2017-2025
Figure: 7.7 Latin America Liquid Biopsy Market (by Prostate Cancer), 2017-2025
Figure: 7.8 Latin America Liquid Biopsy Market (by Colorectal Cancer), 2017-2025
Figure: 7.9 Latin America Liquid Biopsy Market (by Melanoma Cancer), 2017-2025
Figure: 7.10 Latin America Liquid Biopsy Market (by Other Types of Cancer), 2017-2025
Figure: 7.11 Latin America Liquid Biopsy Market (by Non-Oncology), 2017-2025
Figure: 8.1 Latin America Liquid Biopsy Market, 2017-2025
Figure: 8.2 Latin America Liquid Biopsy Market (by Country), 2017-2025
Figure: 8.3 Brazil Liquid Biopsy Market, 2017-2025
Figure: 8.4 Brazil Liquid Biopsy Market (by Therapeutic Application), 2017-2025
Figure: 8.5 Mexico Liquid Biopsy Market, 2017-2025
Figure: 8.6 Mexico: Liquid Biopsy Market (by Therapeutic Application), 2017-2025
Figure: 8.7 Argentina Liquid Biopsy Market, 2017-2025
Figure: 8.8 Argentina: Liquid Biopsy Market (by Therapeutic Application), 2017-2025
Figure: 8.9 Chile Liquid Biopsy Market, 2017-2025
Figure: 8.10 Chile: Liquid Biopsy Market (by Therapeutic Application), 2017-2025
Figure: 8.11 Colombia Liquid Biopsy Market, 2017-2025
Figure: 8.12 Colombia: Liquid Biopsy Market (by Therapeutic Application), 2017-2025
Figure: 8.13 Rest-of-Latin America Liquid Biopsy Market, 2017-2025
Figure: 9.1 Shares of Key Company Profiles
Figure: 9.2 Product Offerings
Figure: 9.3 Biocept, Inc.: Overall Financials, 2015-2017
Figure: 9.4 Biocept, Inc.: R&D Expense, 2015-2017
Figure: 9.5 Biocept, Inc.: SWOT Analysis
Figure: 9.6 Bio-Rad Laboratories, Inc.: Product Offerings
Figure: 9.7 Bio-Rad laboratories, Inc.: Overall Financials, 2015-2017
Figure: 9.8 Bio-Rad Laboratories, Inc.: Revenue (by Business Segment), 2015-2017
Figure: 9.9 Bio-Rad Laboratories, Inc.: Revenue (by Region), 2015-2017
Figure: 9.10 Bio-Rad Laboratories, Inc.: R&D Expense, 2015-2017
Figure: 9.11 Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure: 9.12 Contextual Genomics Inc.: SWOT Analysis
Figure: 9.13 Epic Sciences, Inc.: Product Offerings
Figure: 9.14 Epic Sciences, Inc.: SWOT Analysis
Figure: 9.15 F. Hoffmann-La Roche AG: Product Offerings
Figure: 9.16 F. Hoffmann-La Roche AG: Overall Financials, 2015-2017
Figure: 9.17 F. Hoffmann-La Roche AG: Revenue (by Business Segment), 2015-2017
Figure: 9.18 F. Hoffmann-La Roche Ltd.: Revenue (by Diagnostics Sub-division), 2015-2017
Figure: 9.19 F. Hoffmann-La Roche AG: Revenue (by Region), 2015-2017
Figure: 9.20 F. Hoffmann-La Roche AG: R&D Expense, 2015-2017
Figure: 9.21 F. Hoffmann-La Roche AG: SWOT Analysis
Figure: 9.22 Guardant Health, Inc.: Product Offerings
Figure: 9.23 Guardant Health, Inc.: SWOT Analysis
Figure: 9.24 Illumina, Inc.: Product Offerings
Figure: 9.25 Illumina, Inc.: Overall Financials, 2015-2017
Figure: 9.26 Illumina, Inc.: Revenue (by Business Segment), 2015-2017
Figure: 9.27 Illumina, Inc.: Revenue (by Region), 2015-2017
Figure: 9.28 Illumina, Inc.: R&D Expense, 2015-2017
Figure: 9.29 Illumina, Inc.: SWOT Analysis
Figure: 9.30 MDxHealth, Inc.: Product Offerings
Figure: 9.31 MDxHealth, Inc.: Overall Financials, 2015-2017
Figure: 9.32 MDxHealth, Inc.: R&D Expanse, 2015-2017
Figure: 9.33 MDxHealth, Inc.: SWOT Analysis
Figure: 9.34 Menarini Silicon Biosystems, Inc.: Product Offerings
Figure: 9.35 Menarini Silicon Biosystems, Inc.: SWOT Analysis
Figure: 9.36 Metacell s.r.o: SWOT Analysis
Figure: 9.37 Myriad Genetics, Inc.: Product Offerings
Figure: 9.38 Myriad Genetics, Inc.: Overall Financials, 2015-2017
Figure: 9.39 Myriad Genetics, Inc.: Revenue (by Business Segment), 2015-2017
Figure: 9.40 Myriad Genetics, Inc.: Revenue (by Region), 2015-2017
Figure: 9.41 Myriad Genetics, Inc.: R&D Expense, 2015-2017
Figure: 9.42 Myriad Genetics, Inc.: SWOT Analysis
Figure: 9.43 NeoGenomics Laboratories, Inc.: Product Offerings
Figure: 9.44 NeoGenomics Laboratories, Inc.: Overall Financials, 2015-2017
Figure: 9.45 NeoGenomics Laboratories, Inc.: Revenue (by Business Segment), 2015-2017
Figure: 9.46 NeoGenomics Laboratories, Inc.: R&D Expense, 2015-2017
Figure: 9.47 NeoGenomics Laboratories, Inc.: SWOT Analysis
Figure: 9.48 Qiagen N.V.: Product Offerings
Figure: 9.49 Qiagen N.V.: Overall Financials, 2015-2017
Figure: 9.50 Qiagen N.V.: Revenue (by Business Segment), 2015-2017
Figure: 9.51 Qiagen N.V.: Revenue (by Region), 2015-2017
Figure: 9.52 Qiagen N.V.: R&D Expense, 2015-2017
Figure: 9.53 Qiagen N.V.: SWOT Analysis
Figure: 9.54 Sysmex Inostics GmbH: Product Offerings
Figure: 9.55 Sysmex Inostics GmbH: SWOT Analysis
Figure: 9.56 Thermo Fisher Scientific Inc.: Product Offerings
Figure: 9.57 Thermo Fisher Scientific Inc.: Overall Financials, 2015-2017
Figure: 9.58 Thermo Fisher Scientific Inc.: Revenue (by Business Segment), 2015-2017
Figure: 9.59 Thermo Fisher Scientific Inc.: Revenue (by Region), 2015-2017
Figure: 9.60 Thermo Fisher Scientific Inc.: R&D Expense, 2015-2017
Figure: 9.61 Thermo Fisher Scientific Inc.: SWOT Analysis
Figure: 10.1 Latin America Liquid Biopsy: Market Segmentation
Figure: 10.2 Latin America Liquid Biopsy Market Segmentation
Figure: 10.3 Primary Research
Figure: 10.4 Secondary Research
Figure: 10.5 Data Triangulation
Figure: 10.6 Top-down Approach (Segment-wise Analysis)
Figure: 10.7 Bottom-up Approach (Segment-wise Analysis)
Figure: 10.8 Assumptions and Limitations
Figure: 10.9 Considered Factors for Data Prediction and Modelling
In the healthcare industry, as technological innovations continue to evolve, they open new avenues for better treatment and prevention approaches for infectious and non-infectious diseases globally. The changes and innovations in healthcare industry have the changed the experiences of the patients, outcomes of chronic diseases, and improved practices of healthcare professionals. Significant degree of research on molecular technologies, cancer biomarkers, and biomarkers presence in body fluids has opened various pathways for the development of a vital non-invasive diagnostic procedure such as liquid biopsy.
Biopsies have been used by the healthcare professionals for the diagnosis and treatment of diseases for about 1,000 years. In cancer cases, biopsies help to reveal the genetic profile of the tumor, which enables prediction of disease progression in the patients and their responses to the therapies. Having established that there is a considerable tumor heterogenicity, obtaining multiple tissue biopsies from the patients seemed difficult, owing to the discomfort caused to the patient during the biopsy process, inherent clinical risks coupled with surgical complications, likely to underestimate the complexity associated with the tumor. Technological advancements in the biopsies have helped to overcome these limitations, enabling proper identification of the genetic and epigenetic aberrations. Liquid biopsy help to provide the genetic landscape of all cancerous lesions present in the patients and also helps track the genomic evolution. Cancer is associated with mutated genes and analysis of these tumor-linked genetic alterations is increasing the diagnosis and treatment purpose. According to the key finding published by the Economist Intelligence Unit report in July 2017, the number of cancer cases in Latin America is projected to rise by 91% and deaths by 106% between 2012 and 2035. Use of biomarkers in the liquid biopsy helps to detect the disease easily, understand disease progression and recurrence, and also helps to indicate if a specific treatment can help to reduce the risk associated with the disease.
The purpose of this study is to gain a holistic view of the Latin America liquid biopsy market in terms of various influencing factors, such as recent trends, regulatory frameworks, and technological advancements in the market. The scope of this report constitutes a detailed study of the different kinds of products associated with the Latin America liquid biopsy market. The market has been segmented into “Product Type”, “Circulating Biomarkers”, “Clinical Application”, “Therapeutic Application”, and “Country”. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market.
The Latin America liquid biopsy market is anticipated to reach $70.9 million by 2025, witnessing a CAGR of 10.29% in the forecast period 2019-2025. Some of the factors such as growing prominence for rising prevalence of different types of cancer and requirement of novel diagnostic technologies enabling treatment monitoring. Further, the growing prominence of companion diagnostics and substantial investments made in the field of precision medicine are bolstering the growth of the Latin America liquid biopsy market.
In terms of product type, the Latin America liquid biopsy market is dominated by tests and services. The impressive growth in the demand for tests and services, is attributed to the elevated requirement for non-invasive diagnostic services for treatment selection and monitoring. Further, the growing establishment of molecular diagnostics companies providing liquid biopsy tests with short turnaround times is bolstering the growth of the Latin America liquid biopsy tests and services market.
In terms of circulating biomarkers, the Latin America liquid biopsy market is dominated by circulating tumor DNA (ctDNA). The contribution of the products based on circulating tumor DNA (ctDNA) was valued around 40% of the total Latin America liquid biopsy market revenue. However, the market for products based on circulating tumor cells (CTCs) is anticipated to witness the highest CAGR of 11.75% in the forecast period 2018-2025 and outperform the market for products based on ctDNA.
In terms of clinical applications, the Latin America liquid biopsy market is dominated by treatment monitoring. The contribution of treatment monitoring was valued at $11.6 million in 2017, witnessing a CAGR of 9.74% during the forecast period. The growth can be accounted to the increased awareness and adoption of liquid biopsy tests for the early detection and treatment of cancer.
In terms of therapeutic applications, the Latin America liquid biopsy market is dominated by breast cancer treatment. The growth can be accounted to the increased awareness and adoption of liquid biopsy tests for an early detection and treatment of cancer.
In terms of country, Brazil is the leading contributor to the Latin America liquid biopsy market . This can be attributed to growing geriatric population and rising prevalence of different types of cancer have significantly elevated the requirement of novel diagnostic technologies which enable real-time monitoring of cancer treatment in the country.
The key players who have been contributing significantly to the Latin America liquid biopsy market are Biocept, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche AG, Illumina, Inc., MDxHealth Inc., Myriad Genetics Inc., NeoGenomics Laboratories, Inc., Qiagen N.V., Thermo Fisher Scientific Inc., Guardant Health, Inc., Menarini Silicon Biosystems, Sysmex Inostics GmbH, MetaCell s.r.o, Contextual Genomics Inc., and Epic Sciences, Inc.
We understand that your business need specific answers pertaining to the market. And , therefore, we do provide customised research tailored to your need.
With the purchase of this report, you are entitled to certain degree of free customisation within the scope of the study.
Do get in touch to help us understand how we can serve u better with a custom solution to your research needs. We assure quick turnaround for your pressing business requirements.
Liquid biopsy is a minimal invasive medical procedure with the ability to detect the presence of molecular cancer biomarkers in the biological fluids. The test principally involves the usage of samples of biological fluids, such as blood, urine, serum, and saliva, and then the analysis of the samples using different techniques, such as next-generation sequencing (NGS) and polymerase chain reaction (PCR) to detect the mutations known to cause cancer. The liquid biopsy tests provide a platform to an oncologist for a non-invasive and highly-sensitive tumor profiling of patients. The test provides actionable information about the patients at every critical stage of the treatment cycle. Liquid biopsy tests help in the early detection of tumor-associated mutations in the blood with the help of ctDNA, thus further helping in the betterment of cancer treatment procedure. Growing geriatric population has significantly necessitated the requirement for novel diagnostic procedures based on minimal invasive procedures. Significant degree of research on molecular technologies, cancer biomarkers, and biomarkers presence in body fluids has opened various pathways for the development of a vital non-invasive diagnostic procedure as liquid biopsy.
The purpose of this study is to gain a holistic view of the Latin America liquid biopsy market in terms of various influencing factors, such as recent trends, regulatory frameworks, and technological advancements in the market. The scope of this report constitutes a detailed study of the different kinds of products associated with the Latin America liquid biopsy market. The market has been segmented into “Product Type”, “Circulating Biomarkers”, “Clinical Application”, “Therapeutic Application”, and “Country”. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market.
This research report aims at answering various aspects of the Latin America liquid biopsy market, with the help of the key factors driving the market, restraints and challenges that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The report includes an in-depth examination of the key players and recent developments taking place in this market. Moreover, the report also includes chapters on market dynamics (market drivers, opportunities, and challenges), and industry analysis as well.
The research study highlights the factors governing the industry attractiveness with Porter’s Five Forces for a comprehensive understanding of the Latin America liquid biopsy market. Moreover, the study includes detailed product mapping, market estimation, and analysis of key trends in multiple regions, growth of liquid biopsy market in each region for different cancer types, and the key strategies and developments by the prominent liquid biopsy market stake holders.
The answers to the following key questions can be derived from this report:
• What are the key features of the liquid biopsy technology promoting its incorporation in different clinical applications?
• What are key advantages of the liquid biopsy technology over tissue biopsy?
• How did the liquid biopsy market evolve and what is its scope in the future?
• What are the major market drivers, challenges, and opportunities in the Latin America liquid biopsy market?
• Which are the leading companies dominating the Latin America liquid biopsy market?
• Which therapeutic application market would witness massive incorporation of the liquid biopsy technology in the forecast period?
• Products based on which circulating biomarker are anticipated to witness massive rise in the demand in the forecast period?
• How would the scope of clinical application of the liquid biopsy technology evolve in the forecast period?
• What are investors’ perceptions about the Latin America liquid biopsy market? Also, who are leading stakeholders of the market holding a significant share in the market’s intellectual property?
• What is the market value of the leading segments and sub-segments of the Latin America liquid biopsy market?
• How will each segment of the Latin America liquid biopsy market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2025?
• How will the industry evolve during the forecast period 2019-2025?
• Which region will contribute to the highest rate of sales of the Latin America liquid biopsy market during the forecast period?
The key players who have been contributing significantly to the Latin America liquid biopsy market are Biocept, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche AG, Illumina, Inc., MDxHealth Inc., Myriad Genetics Inc., NeoGenomics Laboratories, Inc., Qiagen N.V., Thermo Fisher Scientific Inc., Guardant Health, Inc., Menarini Silicon Biosystems, Sysmex Inostics GmbH, MetaCell s.r.o, Contextual Genomics Inc., and Epic Sciences, Inc.
List of Tables
Table: 1.1 Tissue Biopsy vs. Liquid Biopsy
Table: 2.1 Impact Analysis
Table: 2.2 Governmental Initiatives for the Market Growth of Precision Medicine
Table: 2.3 Incidence of Leading Cancer Types (by Country), 2018 and 2040
Table: 7.1 Breast Cancer Incidence in Latin American Countries, 2018, 2020, 2025, and 2030
Table: 7.2 Lung Cancer Incidence in Latin American Countries, 2018, 2020, 2025, and 2030
Table: 7.3 Prostate Cancer Incidence in Latin American Countries, 2018, 2020, 2025, and 2030
Table: 7.4 Colorectal Cancer Incidence in Latin American Countries, 2018, 2020, 2025, and 2030
Table: 7.5 Melanoma Cancer Incidence in Latin American Countries, 2018, 2020, 2025, and 2030
Table: 7.6 Ovarian Cancer Incidence in Latin American Countries, 2018, 2020, 2025, and 2030
Table: 7.7 Stomach Cancer Incidence in Latin American Countries, 2018, 2020, 2025, and 2030
Table: 8.1 Healthcare Expenditure (US$ per head) in Latin American Countries, 2015-2017
Table: 8.2 Brazil: Prevalence of Different Types of Cancer, 2018-2030
Table: 8.3 Mexico: Prevalence of Different Types of Cancer, 2018-2030
Table: 8.4 Argentina: Prevalence of Different Types of Cancer, 2018-2030
Table: 8.5 Chile: Prevalence of Different Types of Cancer, 2018-2030
Table: 8.6 Colombia: Prevalence of Different Types of Cancer, 2018-2030
List of Figures
Figure: 1 Few Citations of Liquid Biopsy
Figure: 2 Latin America Market Drivers and Restraints
Figure: 3 Latin America Liquid Biopsy Market, 2017-2025
Figure: 4 Latin America Liquid Biopsy Market (by Product Type), 2017 and 2025
Figure: 5 Latin America Liquid Biopsy Market (by Circulating Biomarkers), 2017 and 2025
Figure: 6 Latin America Liquid Biopsy Market (by Clinical Application), 2017-2025
Figure: 7 Latin America Liquid Biopsy Market (by Therapeutic Application), 2017-2025
Figure: 8 Latin America Liquid Biopsy Market (by Country), 2017-2025
Figure: 9 Adoption Rate: Tissue Biopsy vs. Liquid biopsy
Figure: 1.1 Different Types of Biomarkers in Liquid Biopsy
Figure: 1.2 Evolution of Liquid Biopsy with Progress in Molecular Technologies and Biomarker Discovery
Figure: 1.3 Workflow Model of Tissue and Liquid Biopsy
Figure: 1.4 Clinical Applications of Liquid Biopsy
Figure: 1.5 Latin America Liquid Biopsy Market, 2017-2025
Figure: 2.1 Market Dynamics of LATAM Liquid Biopsy Market
Figure: 3.1 Market Share Analysis: Latin America Liquid Biopsy Market, 2016 and 2017
Figure: 3.2 Porter’s Five Forces Analysis
Figure: 3.3 Bargaining Power of Suppliers: Overall Impact, 2014-2025
Figure: 3.4 Bargaining Power of Buyers: Overall Impact, 2014-2025
Figure: 3.5 Threat of New Entrant: Overall Impact, 2014-2025
Figure: 3.6 Threat of Substitute Products: Overall Impact, 2014-2025
Figure: 3.7 Intensity of Competitive Rivalry: Overall Impact, 2014-2025
Figure: 4.1 Latin America Liquid Biopsy Market (by Circulating Biomarkers)
Figure: 4.2 Liquid Biopsy Market (by Product Type), 2017-2025
Figure: 4.3 Latin America Liquid Biopsy Market (by Tests/Services), 2017-2025
Figure: 4.4 Latin America Liquid Biopsy Market (by Kits and Consumables), 2017-2025
Figure: 4.5 Latin America Liquid Biopsy Market (by Instruments), 2017-2025
Figure: 5.1 Different Circulating Biomarkers
Figure: 5.2 Latin America Liquid Biopsy Market (by Circulating Biomarkers)
Figure: 5.3 Latin America Liquid Biopsy Market (by Circulating Biomarker), 2017 and 2025
Figure: 5.4 Latin America Liquid Biopsy Market (by ctDNA), 2017-2025
Figure: 5.5 CTCs vs. ctDNA Analysis
Figure: 5.6 Latin America Liquid Biopsy Market (by CTCs), 2017-2025
Figure: 5.7 Latin America Liquid Biopsy Market (by cfDNA), 2017-2025
Figure: 5.8 Latin America Liquid Biopsy Market (by Extracellular Vesicles and Others), 2017-2025
Figure: 6.1 Latin America Liquid Biopsy Market (by Clinical Applications)
Figure: 6.2 Liquid Biopsy Market (by Clinical Application), 2017-2025
Figure: 6.3 Latin America Liquid Biopsy Market (by Treatment Monitoring), 2017-2025
Figure: 6.4 Latin America Liquid Biopsy Market (by Prognosis and Recurrence Monitoring), 2017-2025
Figure: 6.5 Latin America Liquid Biopsy Market (by Treatment Selection), 2017-2025
Figure: 6.6 Latin America Liquid Biopsy Market (by Diagnosis and Screening), 2017-2025
Figure: 7.1 Latin America Liquid Biopsy Market (by Therapeutic Applications)
Figure: 7.2 Latin America Liquid Biopsy Market (by Therapeutic Applications), 2017-2025
Figure: 7.3 Types of Breast Cancer
Figure: 7.4 Latin America Liquid Biopsy Market (by Breast Cancer), 2017-2025
Figure: 7.5 Types of Lung Cancer
Figure: 7.6 Latin America Liquid Biopsy Market (by Lung Cancer), 2017-2025
Figure: 7.7 Latin America Liquid Biopsy Market (by Prostate Cancer), 2017-2025
Figure: 7.8 Latin America Liquid Biopsy Market (by Colorectal Cancer), 2017-2025
Figure: 7.9 Latin America Liquid Biopsy Market (by Melanoma Cancer), 2017-2025
Figure: 7.10 Latin America Liquid Biopsy Market (by Other Types of Cancer), 2017-2025
Figure: 7.11 Latin America Liquid Biopsy Market (by Non-Oncology), 2017-2025
Figure: 8.1 Latin America Liquid Biopsy Market, 2017-2025
Figure: 8.2 Latin America Liquid Biopsy Market (by Country), 2017-2025
Figure: 8.3 Brazil Liquid Biopsy Market, 2017-2025
Figure: 8.4 Brazil Liquid Biopsy Market (by Therapeutic Application), 2017-2025
Figure: 8.5 Mexico Liquid Biopsy Market, 2017-2025
Figure: 8.6 Mexico: Liquid Biopsy Market (by Therapeutic Application), 2017-2025
Figure: 8.7 Argentina Liquid Biopsy Market, 2017-2025
Figure: 8.8 Argentina: Liquid Biopsy Market (by Therapeutic Application), 2017-2025
Figure: 8.9 Chile Liquid Biopsy Market, 2017-2025
Figure: 8.10 Chile: Liquid Biopsy Market (by Therapeutic Application), 2017-2025
Figure: 8.11 Colombia Liquid Biopsy Market, 2017-2025
Figure: 8.12 Colombia: Liquid Biopsy Market (by Therapeutic Application), 2017-2025
Figure: 8.13 Rest-of-Latin America Liquid Biopsy Market, 2017-2025
Figure: 9.1 Shares of Key Company Profiles
Figure: 9.2 Product Offerings
Figure: 9.3 Biocept, Inc.: Overall Financials, 2015-2017
Figure: 9.4 Biocept, Inc.: R&D Expense, 2015-2017
Figure: 9.5 Biocept, Inc.: SWOT Analysis
Figure: 9.6 Bio-Rad Laboratories, Inc.: Product Offerings
Figure: 9.7 Bio-Rad laboratories, Inc.: Overall Financials, 2015-2017
Figure: 9.8 Bio-Rad Laboratories, Inc.: Revenue (by Business Segment), 2015-2017
Figure: 9.9 Bio-Rad Laboratories, Inc.: Revenue (by Region), 2015-2017
Figure: 9.10 Bio-Rad Laboratories, Inc.: R&D Expense, 2015-2017
Figure: 9.11 Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure: 9.12 Contextual Genomics Inc.: SWOT Analysis
Figure: 9.13 Epic Sciences, Inc.: Product Offerings
Figure: 9.14 Epic Sciences, Inc.: SWOT Analysis
Figure: 9.15 F. Hoffmann-La Roche AG: Product Offerings
Figure: 9.16 F. Hoffmann-La Roche AG: Overall Financials, 2015-2017
Figure: 9.17 F. Hoffmann-La Roche AG: Revenue (by Business Segment), 2015-2017
Figure: 9.18 F. Hoffmann-La Roche Ltd.: Revenue (by Diagnostics Sub-division), 2015-2017
Figure: 9.19 F. Hoffmann-La Roche AG: Revenue (by Region), 2015-2017
Figure: 9.20 F. Hoffmann-La Roche AG: R&D Expense, 2015-2017
Figure: 9.21 F. Hoffmann-La Roche AG: SWOT Analysis
Figure: 9.22 Guardant Health, Inc.: Product Offerings
Figure: 9.23 Guardant Health, Inc.: SWOT Analysis
Figure: 9.24 Illumina, Inc.: Product Offerings
Figure: 9.25 Illumina, Inc.: Overall Financials, 2015-2017
Figure: 9.26 Illumina, Inc.: Revenue (by Business Segment), 2015-2017
Figure: 9.27 Illumina, Inc.: Revenue (by Region), 2015-2017
Figure: 9.28 Illumina, Inc.: R&D Expense, 2015-2017
Figure: 9.29 Illumina, Inc.: SWOT Analysis
Figure: 9.30 MDxHealth, Inc.: Product Offerings
Figure: 9.31 MDxHealth, Inc.: Overall Financials, 2015-2017
Figure: 9.32 MDxHealth, Inc.: R&D Expanse, 2015-2017
Figure: 9.33 MDxHealth, Inc.: SWOT Analysis
Figure: 9.34 Menarini Silicon Biosystems, Inc.: Product Offerings
Figure: 9.35 Menarini Silicon Biosystems, Inc.: SWOT Analysis
Figure: 9.36 Metacell s.r.o: SWOT Analysis
Figure: 9.37 Myriad Genetics, Inc.: Product Offerings
Figure: 9.38 Myriad Genetics, Inc.: Overall Financials, 2015-2017
Figure: 9.39 Myriad Genetics, Inc.: Revenue (by Business Segment), 2015-2017
Figure: 9.40 Myriad Genetics, Inc.: Revenue (by Region), 2015-2017
Figure: 9.41 Myriad Genetics, Inc.: R&D Expense, 2015-2017
Figure: 9.42 Myriad Genetics, Inc.: SWOT Analysis
Figure: 9.43 NeoGenomics Laboratories, Inc.: Product Offerings
Figure: 9.44 NeoGenomics Laboratories, Inc.: Overall Financials, 2015-2017
Figure: 9.45 NeoGenomics Laboratories, Inc.: Revenue (by Business Segment), 2015-2017
Figure: 9.46 NeoGenomics Laboratories, Inc.: R&D Expense, 2015-2017
Figure: 9.47 NeoGenomics Laboratories, Inc.: SWOT Analysis
Figure: 9.48 Qiagen N.V.: Product Offerings
Figure: 9.49 Qiagen N.V.: Overall Financials, 2015-2017
Figure: 9.50 Qiagen N.V.: Revenue (by Business Segment), 2015-2017
Figure: 9.51 Qiagen N.V.: Revenue (by Region), 2015-2017
Figure: 9.52 Qiagen N.V.: R&D Expense, 2015-2017
Figure: 9.53 Qiagen N.V.: SWOT Analysis
Figure: 9.54 Sysmex Inostics GmbH: Product Offerings
Figure: 9.55 Sysmex Inostics GmbH: SWOT Analysis
Figure: 9.56 Thermo Fisher Scientific Inc.: Product Offerings
Figure: 9.57 Thermo Fisher Scientific Inc.: Overall Financials, 2015-2017
Figure: 9.58 Thermo Fisher Scientific Inc.: Revenue (by Business Segment), 2015-2017
Figure: 9.59 Thermo Fisher Scientific Inc.: Revenue (by Region), 2015-2017
Figure: 9.60 Thermo Fisher Scientific Inc.: R&D Expense, 2015-2017
Figure: 9.61 Thermo Fisher Scientific Inc.: SWOT Analysis
Figure: 10.1 Latin America Liquid Biopsy: Market Segmentation
Figure: 10.2 Latin America Liquid Biopsy Market Segmentation
Figure: 10.3 Primary Research
Figure: 10.4 Secondary Research
Figure: 10.5 Data Triangulation
Figure: 10.6 Top-down Approach (Segment-wise Analysis)
Figure: 10.7 Bottom-up Approach (Segment-wise Analysis)
Figure: 10.8 Assumptions and Limitations
Figure: 10.9 Considered Factors for Data Prediction and Modelling
In the healthcare industry, as technological innovations continue to evolve, they open new avenues for better treatment and prevention approaches for infectious and non-infectious diseases globally. The changes and innovations in healthcare industry have the changed the experiences of the patients, outcomes of chronic diseases, and improved practices of healthcare professionals. Significant degree of research on molecular technologies, cancer biomarkers, and biomarkers presence in body fluids has opened various pathways for the development of a vital non-invasive diagnostic procedure such as liquid biopsy.
Biopsies have been used by the healthcare professionals for the diagnosis and treatment of diseases for about 1,000 years. In cancer cases, biopsies help to reveal the genetic profile of the tumor, which enables prediction of disease progression in the patients and their responses to the therapies. Having established that there is a considerable tumor heterogenicity, obtaining multiple tissue biopsies from the patients seemed difficult, owing to the discomfort caused to the patient during the biopsy process, inherent clinical risks coupled with surgical complications, likely to underestimate the complexity associated with the tumor. Technological advancements in the biopsies have helped to overcome these limitations, enabling proper identification of the genetic and epigenetic aberrations. Liquid biopsy help to provide the genetic landscape of all cancerous lesions present in the patients and also helps track the genomic evolution. Cancer is associated with mutated genes and analysis of these tumor-linked genetic alterations is increasing the diagnosis and treatment purpose. According to the key finding published by the Economist Intelligence Unit report in July 2017, the number of cancer cases in Latin America is projected to rise by 91% and deaths by 106% between 2012 and 2035. Use of biomarkers in the liquid biopsy helps to detect the disease easily, understand disease progression and recurrence, and also helps to indicate if a specific treatment can help to reduce the risk associated with the disease.
The purpose of this study is to gain a holistic view of the Latin America liquid biopsy market in terms of various influencing factors, such as recent trends, regulatory frameworks, and technological advancements in the market. The scope of this report constitutes a detailed study of the different kinds of products associated with the Latin America liquid biopsy market. The market has been segmented into “Product Type”, “Circulating Biomarkers”, “Clinical Application”, “Therapeutic Application”, and “Country”. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market.
The Latin America liquid biopsy market is anticipated to reach $70.9 million by 2025, witnessing a CAGR of 10.29% in the forecast period 2019-2025. Some of the factors such as growing prominence for rising prevalence of different types of cancer and requirement of novel diagnostic technologies enabling treatment monitoring. Further, the growing prominence of companion diagnostics and substantial investments made in the field of precision medicine are bolstering the growth of the Latin America liquid biopsy market.
In terms of product type, the Latin America liquid biopsy market is dominated by tests and services. The impressive growth in the demand for tests and services, is attributed to the elevated requirement for non-invasive diagnostic services for treatment selection and monitoring. Further, the growing establishment of molecular diagnostics companies providing liquid biopsy tests with short turnaround times is bolstering the growth of the Latin America liquid biopsy tests and services market.
In terms of circulating biomarkers, the Latin America liquid biopsy market is dominated by circulating tumor DNA (ctDNA). The contribution of the products based on circulating tumor DNA (ctDNA) was valued around 40% of the total Latin America liquid biopsy market revenue. However, the market for products based on circulating tumor cells (CTCs) is anticipated to witness the highest CAGR of 11.75% in the forecast period 2018-2025 and outperform the market for products based on ctDNA.
In terms of clinical applications, the Latin America liquid biopsy market is dominated by treatment monitoring. The contribution of treatment monitoring was valued at $11.6 million in 2017, witnessing a CAGR of 9.74% during the forecast period. The growth can be accounted to the increased awareness and adoption of liquid biopsy tests for the early detection and treatment of cancer.
In terms of therapeutic applications, the Latin America liquid biopsy market is dominated by breast cancer treatment. The growth can be accounted to the increased awareness and adoption of liquid biopsy tests for an early detection and treatment of cancer.
In terms of country, Brazil is the leading contributor to the Latin America liquid biopsy market . This can be attributed to growing geriatric population and rising prevalence of different types of cancer have significantly elevated the requirement of novel diagnostic technologies which enable real-time monitoring of cancer treatment in the country.
The key players who have been contributing significantly to the Latin America liquid biopsy market are Biocept, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche AG, Illumina, Inc., MDxHealth Inc., Myriad Genetics Inc., NeoGenomics Laboratories, Inc., Qiagen N.V., Thermo Fisher Scientific Inc., Guardant Health, Inc., Menarini Silicon Biosystems, Sysmex Inostics GmbH, MetaCell s.r.o, Contextual Genomics Inc., and Epic Sciences, Inc.
We understand that your business need specific answers pertaining to the market. And , therefore, we do provide customised research tailored to your need.
With the purchase of this report, you are entitled to certain degree of free customisation within the scope of the study.
Do get in touch to help us understand how we can serve u better with a custom solution to your research needs. We assure quick turnaround for your pressing business requirements.
